Ключевые слова:
obesity, prediabetes, peripheral polyneuropathy, vitamin D, homocysteine, hyaluronic acid, hormonal markers.Библиографические ссылки
Callaghan BC, et al. Metabolic syndrome components as risk factors for neuropathy. Ann Neurol. 2020;87:684–693.
Feldman EL, et al. Diabetic neuropathy. Nat Rev Dis Primers. 2019;5:41.
Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266–281.
Jiang D, et al. Hyaluronic acid and inflammation in peripheral nerves. J Neuroinflammation. 2018;15:119.
Malik RA, et al. Biomarkers for diabetic neuropathy. Diabetologia. 2017;60:1000–1010.
Pezzoli G, et al. Thyroid dysfunction and peripheral neuropathy. Clin Endocrinol (Oxf). 2016;85(1):50–57.
Pop-Busui R, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017;40:136–154.
Robinson K, et al. Hyperhomocysteinemia as a risk factor for peripheral neuropathy. Neurology. 2021;96(4):e532–e540.
Shehab D, Abdella N. Vitamin D deficiency and peripheral neuropathy in patients with prediabetes. Diabetes Care. 2019;42(10):1936–1943.
Smith AG, Singleton JR. Idiopathic and prediabetic neuropathies. Curr Diab Rep. 2018;18(12):126.
Stanger O, et al. Homocysteine in health and disease. Clin Chem Lab Med. 2009;47(5):445–454.
Tesfaye S, Selvarajah D. Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. Diabetes Metab Res Rev. 2017;33(6):e2881.
Vinik AI, Casellini CM. Treatment of diabetic neuropathy: recent advances. Curr Opin Endocrinol Diabetes Obes. 2013;20:141–151.
Vinik AI, et al. Mechanisms of diabetic neuropathy. Diabetes Care. 2013;36:1772–1781.
Ziegler D, et al. Prevalence of polyneuropathy in prediabetic states. Diabetes Care. 2015;38:200–207.
